The Bioactive Team
Rick worked for several years in the pharmaceutical industry in London, England, having experience within both pharmaceutical research and production environments, specialising in ‘Translational Medicine’ as a software engineer.
In addition to biotech, he has been involved in many industries from taxation and telecommunications, to agro-forestry & livestock, specialising in innovative projects and transformational business design.
Rick has been a guest technology lecturer at Murdoch University. He has a commerce/technology degree from Curtin University in Perth, Western Australia.
Since 2000, Rick has been developing and commercialising innovation. His passion for innovation is to save time, money & improve the quality of life.
Tony is currently Professor at the Griffith Institute for Drug Discovery. He specialises in Biodiscovery involving screening against molecular targets, isolation and structure elucidation of bioactive natural products.
His network of affiliate researchers and research institutions spans across the globe as does his reputation within the field of new compound discoveries.
Paul has facilitated commercial deals in areas such as novel therapeutics, biomarkers, medical devices and other technologies developed by Australian biotech companies and research institutions.
He has held senior management positions at Austrade, Bio-Link, ATP Innovations, Cellabs and the University of Technology, Sydney (UTS) and currently serves on the Boards of the Victoria Cancer Biobank and the Global Health Alliance Melbourne.
Darren has a passion for biotech and natural health commercialisation, business development, licensing and business transformation. He is currently the COO of Fitgenes.
Darren is an experienced biotech senior executive with qualifications in both business (MBA) and science (PhD). His senior management experience includes start-up biotech, ASX listed and unlisted entities.
As a private company in the early stages of commercialisation, the wider Bioactive Team is made up of consultants and contract organisations. Bioactive adopts a lean approach to investor funds by not appointing permanent paid board members. Bioactive has an array of mentor and advisory who span several disciplines.
Potential investors can find out more by contacting Rick Ferdinands through the Contact Us link.